InsidersTradesSigma
Total declarations
Companies
▲ Purchases (85 ops.)
▼ Sales (9 ops.)
Insider track record
OtherDisclosed buys
85
Disclosed sells
9
T+90 hit rate
23%
T+90 mean return
-7.8%
Across 40 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the full record of transactions filed by Cormorant Asset Management, LP. Officer active across 19 companies, notably Verve Therapeutics, Inc.. In total, 170 filings have been logged. Breakdown: 85 buys · 9 sells. Total volume traded: €692.2m. History available since 26 May 2021. The latest transaction was filed on 3 June 2026 (Attribution). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations170 total
31,000 sharesCommon StockSEC:0001231919-26-000711:0
Ideal exit: 22 Mar 2027 (T+270)
1,876 sharesCommon StockSEC:0001231919-26-000711:1
Ideal exit: 23 Mar 2027 (T+270)
124,893 sharesCommon StockSEC:0001231919-26-000656:2
Ideal exit: 13 Mar 2027 (T+270)
15,414 sharesCommon StockSEC:0001231919-26-000656:1
Ideal exit: 12 Mar 2027 (T+270)
391,019 sharesCommon StockSEC:0001231919-26-000656:0
Ideal exit: 9 Mar 2027 (T+270)
479,039 sharesCommon StockSEC:0001231919-26-000625:0
Ideal exit: 6 Mar 2027 (T+270)
103 sharesCommon StockSEC:0001231919-26-000625:1
Ideal exit: 7 Mar 2027 (T+270)
548,580 sharesCommon StockSEC:0001231919-26-000625:2
Ideal exit: 8 Mar 2027 (T+270)
35,500 shares0Common StockSEC:0001231919-26-000604:0
6,387 shares@ US$24.90100.0% of flowCommon StockSEC:0001231919-26-000495
Ideal exit: 6 Feb 2027 (T+270)
6,387 shares@ US$24.9050.0% of flowCommon StockSEC:0001231919-26-000495:0
Ideal exit: 6 Feb 2027 (T+270)
1,813,439 shares@ US$1.854598.6% of flowClass A Common StockSEC:0000929638-25-001950:0
320,913 shares@ US$0.862.4% of flowCommon StockSEC:0001415889-25-012942:0
Ideal exit: 6 Feb 2026 (T+270)
24,300 shares@ US$1.9851.4% of flowClass A Common StockSEC:0000929638-25-001870:0
1,062,326 sharesCommon StockSEC:0001415889-25-011583:0
1,296,296 shares@ US$13.5043.5% of flowCommon StockSEC:0001415889-25-008257:0
Ideal exit: 8 Dec 2025 (T+270)
304,287 shares@ US$30.5613.7% of flowCommon StockSEC:0001415889-25-007443:0
Ideal exit: 30 Nov 2025 (T+270)
800,189 sharesCommon StockSEC:0000929638-25-000822:0
5,021,990 sharesCommon StockSEC:0001415889-25-003504:0
5,714,285 shares@ US$8.7536.4% of flowCommon StockSEC:0001415889-25-002760:0
Ideal exit: 27 Oct 2025 (T+270)
16,897,159 sharesCommon StockSEC:0001415889-24-030247:0
535,000 shares0Common StockSEC:0001415889-24-028837:0
389,716 shares@ US$14.912100.0% of flowCommon StockSEC:0001415889-24-027924:0
1,220,681 shares@ US$16.2532.3% of flowCommon StockSEC:0001415889-24-026718:0
Ideal exit: 5 Aug 2025 (T+270)
184,331 shares@ US$21.7078.8% of flowCommon SharesSEC:0000929638-24-003752:0
Ideal exit: 1 Aug 2025 (T+270)
25 of 170 declarations
About Cormorant Asset Management, LP
Cormorant Asset Management, LP is a significant shareholder of Verve Therapeutics, Inc.
